Neurocrine to Acquire Soleno for Prader-Willi Syndrome Drug

Neurocrine Biosciences announced its agreement to acquire Soleno Therapeutics, gaining access to its late-stage drug for Prader-Willi syndrome, a rare genetic disorder causing relentless hunger.